Experimental Pancreatic Cancer Pill Improves Survival in Study

An experimental pill developed by Revolution Medicines has shown improved survival rates for patients with late-stage pancreatic cancer in a recent study. This breakthrough offers new hope for those battling the aggressive disease.

15 Apr, 12:53 — 15 Apr, 12:53

Post Share

Sources

Showing 1 of 2 sources

France 24High138d ago

Experimental pancreatic cancer pill helps improve survival in late-stage study

Revolution Medicines' experimental oral drug ⁠helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months for ‌those who were given intravenous cytotoxic chemotherapy, the standard ⁠of care, the company said on Monday.

By FRANCE24

Read full article →

Coverage Timeline

First report: meta-mk · 15 Apr, 07:48|Full coverage: 2 · 5h|Window: 5h

Left-leaningCenterRight-leaning

meta-mk15 Apr, 07:48First to report

Експерименталната таблета против рак на „Револушн Медисинс“ го зголемува преживувањето кај пациентите

5h later

France 2415 Apr, 12:53Latest update

Experimental Pancreatic Cancer Pill Improves Survival in Study

Sources

Experimental pancreatic cancer pill helps improve survival in late-stage study

Coverage Timeline

Експерименталната таблета против рак на „Револушн Медисинс“ го зголемува преживувањето кај пациентите

Experimental pancreatic cancer pill helps improve survival in late-stage study

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests